Type 2 diabetes: symptoms, causes and treatments in Morocco

01Understanding type 2 diabetes: a Moroccan epidemic#

Type 2 diabetes (T2D) is one of the most common chronic conditions in the world, and Morocco is no exception to the epidemic that is gradually engulfing the global population. Medically, it is defined as chronic elevation of blood glucose resulting from a combination of two distinct but often overlapping pathophysiological mechanisms: insulin resistance at the level of peripheral tissues (muscle, liver, adipose tissue) that no longer respond properly to the regulating hormone, and progressive failure of insulin secretion by the pancreatic beta cells, which can no longer compensate for that resistance.

T2D accounts for roughly 90% of all diabetes cases worldwide, and must be distinguished from type 1 diabetes (autoimmune, typically beginning in childhood or young adulthood and requiring insulin from the outset), gestational diabetes that appears during pregnancy, and several rarer forms (MODY, drug-induced or pancreatic-disease–related diabetes). What makes T2D distinctive is its progressive nature, its close relationship with lifestyle (excess weight, inactivity, diet) and the possibility of prevention or even remission under certain conditions.

In Morocco, according to the Ministry of Health and Social Protection and the National Population and Family Health Survey (ENPSF), about 2 million Moroccans live with T2D, or close to 10% of the adult population. The prevalence has doubled in two decades and continues to climb rapidly, driven by several converging factors: an ageing population (prevalence rises sharply with age, reaching 25–30% after 65), rapid urbanisation that reshapes lifestyles, the westernisation of diets with greater consumption of ultra-processed foods, fast-acting sugars and sugary drinks, the obesity epidemic (53% of Moroccan adults are overweight, 20% obese), and the sedentary lifestyle linked to motorisation and urban living. To those 2 million diagnosed patients should be added likely several hundred thousand undiagnosed people with diabetes, which is why active screening matters.

Diabetes is now affecting younger and younger adults in Morocco, with a worrying decline in the average age at diagnosis. While T2D historically appeared after age 40–50, we now see cases as early as the thirties or even adolescence in severely overweight patients, particularly in urban environments. This trend accelerates the cumulative risk of long-term complications and justifies particularly rigorous management in younger patients.

02Recognising the symptoms of diabetes#

T2D has a fearsome characteristic: it can progress silently for years without any obvious symptoms while the elevated blood sugar gradually damages vessels and organs. That is why many patients only learn they have diabetes by chance during a routine blood test, or worse, on the occasion of a revealing complication (heart attack, stroke, non-healing foot ulcer, sudden vision loss, severe infection).

When symptoms do appear, they typically reflect chronically very high blood glucose (often above 2.5–3 g/L). The classic signs are worth knowing. Polyuria (frequent urination, day and night) results from the elimination of excess glucose in urine, which drags large amounts of water with it. Polydipsia (excessive, constant thirst) is the direct consequence of polyuria-induced dehydration. Persistent unexplained fatigue is very common, linked both to the cells' inability to use glucose for energy effectively and to dehydration. Blurred vision or drops in visual acuity may occur, related to osmotic shifts in the lens.

Other, more subtle signs deserve attention. Unintentional weight loss despite a preserved or even increased appetite reflects the body's inability to use glucose properly, which is excreted in urine instead of stored and consumed. Abnormally slow wound healing, particularly on the feet, is highly suggestive. Recurrent skin infections (mycoses, abscesses, intertrigos), repeated urinary tract infections in women, genital mycoses (candidiasis) in both sexes reflect the immune impairment induced by hyperglycaemia. Tingling or numbness in the feet, sometimes the hands, may reveal early diabetic neuropathy.

If several of these symptoms appear, especially in an at-risk individual (overweight, family history, over 40), a prompt medical consultation is needed for a glucose work-up. The golden rule: don't wait for symptoms before screening — a regular fasting glucose test in at-risk individuals lets us detect diabetes at an asymptomatic stage where management is simpler and complications still preventable.

03Modifiable and non-modifiable risk factors#

T2D arises from a complex interaction between genetic and environmental factors. Identifying these factors helps stratify individual risk and act on those that can be changed.

Non-modifiable risk factors

A family history of diabetes is one of the most powerful risk factors. Having a first-degree relative (father, mother, sibling) with diabetes multiplies risk 2 to 4 fold. Having both parents with diabetes multiplies it by 5 to 6. This hereditary component is particularly pronounced in Maghreb populations, which partly explains the high prevalence of diabetes in Morocco. Genetic epidemiology studies have identified several susceptibility genes (TCF7L2, PPARG, KCNJ11) that do not cause disease in isolation but interact with the environment to raise risk.

Age is a major factor: risk rises gradually after 40, peaks around 60–70, and remains elevated in very old people. Ageing is accompanied by a physiological decline in insulin sensitivity and pancreatic secretion. Sex plays a moderate role, with a slight male predominance before 65 that reverses thereafter. Ethnic origin is important: populations from North Africa, sub-Saharan Africa, South Asia and Pacific islands have a more pronounced genetic predisposition than Northern European populations.

A history of gestational diabetes in women multiplies the later risk of T2D sevenfold within 10 years of pregnancy, justifying lifelong annual metabolic follow-up in these patients. Having delivered a baby weighing more than 4 kg (macrosomia) is also a sign of increased risk. Polycystic ovary syndrome (PCOS), common in young women, is associated with insulin resistance that predisposes to later diabetes.

Modifiable risk factors

Modifiable risk factors are the main target of prevention and early management. Overweight and obesity are the leading modifiable risk factors — they are involved in about 80% of T2D cases. Abdominal fat (waist circumference greater than 94 cm in men and 80 cm in women) is particularly harmful because visceral adipose tissue releases pro-inflammatory substances and free fatty acids that worsen insulin resistance. A weight loss of 5 to 10% is enough to significantly improve insulin sensitivity and may prevent or even reverse early-stage diabetes.

Sedentary behaviour is an independent factor: less than 150 minutes of moderate physical activity per week roughly doubles the risk. Regular physical activity improves muscular glucose uptake even independently of weight loss. Unbalanced diets are another major factor: regimens rich in fast-acting sugars (sodas, juices, pastries), ultra-processed foods, processed meats, excess red meat, and poor in fibre, fruit, vegetables, fish and legumes. In Morocco, several cultural eating habits favour diabetes: large quantities of salty industrial bread, daily sweetened tea, traditional pastries that are very rich in sugar, large quantities of dates, particularly during Ramadan.

Uncontrolled arterial hypertension is associated with diabetes within the metabolic syndrome and amplifies cardiovascular risk in both directions. Dyslipidaemia (high LDL, low HDL, high triglycerides) often accompanies diabetes and forms a major cardiovascular risk cluster. Tobacco use significantly raises T2D risk and dramatically worsens its cardiovascular complications. Excessive alcohol consumption, poorly managed chronic stress and chronic sleep deprivation (less than 6 hours per night) are also linked to a moderate increase in risk.

04Diagnosing diabetes in Morocco#

Diagnosis of T2D is biological and rests on three validated tests, available in every medical analysis laboratory in Morocco.

Fasting blood glucose measures blood sugar after at least 8 hours of fasting (typically in the morning before breakfast). Diabetes is diagnosed when fasting glucose is greater than or equal to 1.26 g/L (7 mmol/L) on two separate measurements. Glucose between 1.10 and 1.25 g/L corresponds to prediabetes (impaired fasting glucose) and warrants lifestyle measures to prevent progression to diabetes. The cost of this test in Morocco is 40 to 80 MAD depending on the laboratory, reimbursed at 70–80% by the AMO.

Glycated haemoglobin (HbA1c), expressed as a percentage, reflects average blood glucose over the previous 2 to 3 months through irreversible binding of glucose to red blood cell haemoglobin. Diabetes is diagnosed when HbA1c is greater than or equal to 6.5% (48 mmol/mol). HbA1c between 5.7 and 6.4% also defines prediabetes. HbA1c has the advantages of not requiring fasting and reflecting an average glycaemic state over weeks, which makes it the reference test for monitoring people with diabetes. Cost in Morocco: 150 to 250 MAD, partially reimbursed.

The oral glucose tolerance test (OGTT) measures blood glucose 2 hours after ingesting a 75 g glucose solution. Diagnosis is made for a 2-hour glucose level greater than or equal to 2 g/L (11.1 mmol/L). This more cumbersome test is mainly used as a second line, particularly for screening gestational diabetes in women.

Several complementary tests are systematically prescribed at diagnosis and during follow-up: a complete lipid panel (total cholesterol, HDL, LDL, triglycerides), renal function (creatinine and eGFR, microalbuminuria), urine dipstick (looking for glucose, proteins, ketones), liver panel (transaminases — fatty liver is very common in patients with diabetes), TSH (to rule out associated thyroid disease), a baseline ECG, an annual fundus exam (screening for diabetic retinopathy), and a regular podiatric check-up (looking for neuropathy and arteriopathy).

Diabetes screening in asymptomatic adults is recommended from age 45 with annual fasting glucose, or earlier (from age 35) in at-risk individuals (family history, overweight, hypertension, dyslipidaemia, history of gestational diabetes). Free screening is offered in Health Centres and during national campaigns (World Diabetes Day on 14 November every year).

05Therapeutic management#

Treatment of T2D has evolved considerably in recent decades, with a personalised approach today based on patient profile and comorbidities. Moroccan guidelines follow the international standards of the ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes), adapted to the local context.

Lifestyle measures, the foundation of treatment

Lifestyle measures are the indispensable foundation of treatment, always the first line and maintained even when medication is added. They are effective on their own in 30–40% of newly diagnosed cases and improve the results of every drug class when applied rigorously.

Weight loss in overweight patients is the most powerful measure. A loss of 5 to 10% of initial body weight reduces HbA1c by 0.5 to 1% and can reverse early diabetes. Patients with morbid obesity who undergo bariatric surgery and lose 25 to 40 kg often experience complete remission of diabetes. Dietary modification favours the Mediterranean pattern: vegetables in abundance at every meal, fresh whole fruit (limited to 2–3 a day for their sugar content), legumes 3–4 times a week, fish 2–3 times a week, white rather than red meat, whole rather than refined grains, olive oil as the main source of fat, nuts in moderation. Strictly limit added sugars, sugary drinks (sodas, industrial juices, very sweet tea), traditional pastries, white industrial bread, white rice, fried foods, fatty processed meats, alcohol.

Regular physical activity is essential. The recommended target is at least 150 minutes per week of moderate aerobic activity (brisk walking, swimming, cycling, dancing), ideally spread over 5 days, complemented by 2 weekly resistance-training sessions that improve insulin sensitivity. Physical activity lowers blood glucose during exertion and improves insulin sensitivity for 24 to 48 hours after exercise. Complete smoking cessation delivers a major benefit on overall cardiovascular risk. Stress management through validated techniques (meditation, sophrology, yoga, physical activity) contributes to better glycaemic control.

Oral antidiabetic medications

When lifestyle measures are insufficient (the most common case), drug therapy is introduced. Metformin (Glucophage and many generics) is the first-line treatment in nearly all patients without contraindications (severe renal failure). It acts mainly by reducing hepatic glucose production and improving insulin sensitivity. Excellent tolerance, no risk of hypoglycaemia in monotherapy, neutral or even favourable effect on weight, demonstrated cardiovascular benefit, and a very affordable cost in Morocco starting at 20 MAD per month. Side effects are mainly digestive (nausea, diarrhoea) at the start, generally transient.

Sulfonylureas (glibenclamide, gliclazide, glimepiride) stimulate pancreatic insulin secretion. They are effective but expose patients to hypoglycaemia risk and lead to slight weight gain. Glibenclamide, an older long-acting agent, is increasingly being replaced by gliclazide (Diamicron) with a more favourable profile. Monthly cost: 30–100 MAD.

DPP-4 inhibitors or gliptins (sitagliptin/Januvia, vildagliptin/Galvus, linagliptin/Trajenta) extend the action of natural incretins that stimulate insulin secretion in response to meals. Excellent tolerance, no hypoglycaemia in monotherapy, weight-neutral. Monthly cost 200–500 MAD, partially reimbursed under ALD.

SGLT2 inhibitors (dapagliflozin/Forxiga, empagliflozin/Jardiance) represent a major recent therapeutic innovation. They promote urinary elimination of excess glucose and provide cardiovascular and renal benefit independent of glycaemic control, which makes them treatments of choice in patients with diabetes plus cardiovascular disease or chronic kidney disease. Main side effects: urinary tract infections and genital mycoses due to glycosuria. Monthly cost 400–700 MAD, reimbursed under ALD.

GLP-1 agonists (liraglutide/Victoza, semaglutide/Ozempic, dulaglutide/Trulicity), originally available only as subcutaneous injections but now also as oral tablets (oral semaglutide/Rybelsus), are synthetic incretin hormones that strongly stimulate insulin secretion, suppress glucagon, increase satiety and produce significant weight loss (5–15% depending on the molecule). Cardiovascular and renal benefit is demonstrated for several molecules. Monthly cost is high (3,500–5,500 MAD for semaglutide), reimbursed under ALD for diabetes.

Insulin therapy

When oral and non-insulin injectable antidiabetics fail to achieve glycaemic targets (HbA1c generally below 7%, sometimes 6.5% in young patients without hypoglycaemia risk, more permissive in frail elderly patients), insulin therapy is introduced. It can begin with a single evening dose of long-acting insulin (long-acting analogues: glargine/Lantus, detemir/Levemir, degludec/Tresiba) added to oral antidiabetics — a simple, well-tolerated regimen. If insufficient, the schedule moves to basal-bolus, with long-acting insulin in the evening and rapid-acting insulin (aspart/Novorapid, lispro/Humalog, glulisine/Apidra) before each meal. Various pre-filled pens and vials are available in Morocco at prices from 100 to 400 MAD depending on the type, reimbursed at 100% under ALD. Insulin therapy requires rigorous therapeutic education (injection technique, self-monitoring, hypoglycaemia management, dose adjustment).

Bariatric surgery in patients with obesity and diabetes

In severely obese patients (BMI greater than 35) with poorly controlled diabetes despite well-conducted medical treatment, bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) can lead to complete diabetes remission in 50 to 80% of cases, depending on the technique and patient profile. Gastric bypass is particularly effective, with early metabolic effects that are independent of weight loss. Several clinics in Casablanca, Rabat and Marrakech perform these interventions, partially reimbursed by the AMO under ALD.

06Social and financial coverage#

Diabetes is on the list of Long-Term Conditions (Affections de Longue Durée, ALD) in Morocco, which entitles patients to enhanced coverage by health insurance schemes. This recognition reflects the epidemiological and economic importance of diabetes and ensures patients can access essential care without financial hardship.

In practice, ALD coverage includes 100% reimbursement of medications on the reimbursable list (metformin, sulfonylureas, gliptins, insulins), glucose monitoring strips (with quotas based on treatment type), glucose meters (one every 3–5 years), specialist consultations (endocrinologist, ophthalmologist for fundus, cardiologist, nephrologist), biological follow-up tests (quarterly HbA1c, annual microalbuminuria, annual lipid panel), and complication-screening tests (annual fundus, ECG, lower-limb arterial Doppler ultrasound where indicated, podiatric check-up).

For beneficiaries of CNOPS (civil servants) and CNSS (private-sector employees), access is facilitated by hospital agreements and conventionned pharmacies with third-party payment. For beneficiaries of AMO Tadamon (rolled out from December 2022 to replace RAMED), coverage is now effective with access to the same services in public and conventionned facilities. This extension to roughly 11 million low-income Moroccans is a major step forward that significantly reduces inequalities in access to diabetes care.

Complementary health insurance (private mutuals) can supplement this coverage, particularly for medications outside the basic AMO list, fee overruns, and non-reimbursed services. For low-income patients or those in precarious situations, several associations (Moroccan League against Diabetes, Mohammed V Foundation for Solidarity) and charitable centres offer free access to care, medications and strips.

07Living with diabetes day-to-day#

With good medical follow-up and good self-management, a person with T2D can lead an almost normal life with preserved life expectancy. Diabetes is not a fatality — it is a chronic condition that demands daily attention but that is well managed in the great majority of cases.

Capillary blood-glucose self-monitoring is essential for patients on insulin (4 to 6 daily measurements), useful for those on sulfonylureas at risk of hypoglycaemia (1 to 3 daily measurements), and more limited for patients on metformin alone (1 to 2 occasional checks per week). Continuous glucose monitoring (CGM) systems such as Freestyle Libre are growing and offer considerable comfort for patients on insulin, now partially available in Morocco.

HbA1c testing every 3 months assesses overall glycaemic control and guides treatment adjustments. The standard target is below 7%, stricter (6 to 6.5%) in young people without complications, more permissive (7.5 to 8%) in frail elderly patients or those with advanced complications. The annual fundus exam by an ophthalmologist screens for diabetic retinopathy (the leading cause of acquired blindness in adults) at a stage where it can be treated by laser photocoagulation or intravitreal injections. The annual renal panel (creatinine, eGFR, microalbuminuria) screens for diabetic nephropathy (the leading cause of end-stage renal disease in Morocco). Foot vigilance is critical: daily inspection, rigorous hygiene, suitable shoes, and quick consultation for any wound or anomaly — a diabetic foot wound can lead to amputation if not addressed early.

Several vaccinations are strongly recommended in patients with diabetes due to immune fragility: annual flu vaccine (October–November), pneumococcal vaccine (per protocol), up-to-date Covid-19 vaccine, and hepatitis B vaccine in unvaccinated young patients with diabetes. Regular cardiovascular follow-up (cardiologist 1–2 times per year, annual ECG, echocardiogram depending on context) is essential because cardiovascular risk is multiplied by 2 to 4 in patients with diabetes.

Ramadan and diabetes

The Ramadan fast is a crucial issue for Moroccan patients with diabetes. According to the IDF-DAR 2021 classification, risk varies by profile. Patients with T2D on metformin alone, well controlled can usually fast without major difficulty. Patients on sulfonylureas must adjust doses or switch molecules to limit hypoglycaemia risk. Patients on insulin can fast under close medical supervision with treatment adjustment. Patients with advanced complications (kidney failure, severe heart disease, history of severe hypoglycaemia) are at very high risk and fasting is generally inadvisable.

A pre-Ramadan consultation 6 to 8 weeks before the holy month is essential to assess risk, adjust treatment, educate on multiple daily self-monitoring and define the thresholds for breaking the fast (glucose below 0.70 g/L or above 3 g/L mandates immediate breaking). Several religious fatwas confirm permission to break the fast in case of vital risk — preserving health takes precedence over ritual observance.

The role of patient education

Therapeutic patient education (TPE) is a pillar that is often under-used in management. It aims to give patients the knowledge and skills they need to actively manage their condition day-to-day: understanding diabetes, adjusting insulin doses, recognising and treating hypoglycaemia, practical balanced eating, suitable physical activity, foot care, travel and holidays. Several Moroccan centres now offer structured individual or group TPE programmes that significantly improve long-term outcomes.

08Prevention: act early to avoid diabetes#

For people at risk but not yet diabetic (prediabetes, overweight, family history), preventive measures can reduce the risk of developing diabetes by 50 to 60%, as the landmark Diabetes Prevention Program study showed. These measures include a 5 to 10% weight loss, regular physical activity of at least 150 minutes per week, and a balanced Mediterranean-style diet. In very high-risk individuals, metformin can be offered preventively, with about 30% risk reduction — less effective than lifestyle changes.

At a collective level, several levers should be activated to curb the epidemic: nutritional education from school onwards, taxes on sugary drinks, regulation of food advertising, urban planning that supports physical activity, and organised screening of at-risk individuals. The National Plan to Combat Diabetes of the Ministry of Health is working on these axes with the goal of stabilising and then reversing the disease's progression in the coming decades.

The essential message: type 2 diabetes is a major condition but is largely preventable and well treatable. The diagnostic and therapeutic tools available today in Morocco enable quality care, and the vast majority of patients can lead a full and active life with their disease, provided they engage actively in their follow-up and benefit from structured medical support.